User Fees, ‘Cures,’ Elections: FDA Bracing For The Crash
Executive Summary
Negotiating new user fee deal with industry will be difficult without knowing scope of agency’s new responsibilities from pending reform legislation, acting FDA chief Ostroff notes, but shape of that bill itself may depend on next elections.